Ningbo Sinutra

Sinutra Pharmaceutical is a clinical-stage biopharmaceutical company based in Ningbo, China, specializing in the discovery and development of innovative small molecule therapeutics. The company leverages its proprietary structure-based drug design (SBDD) and fragment-based drug discovery (FBDD) platforms to target high-value biological pathways in metabolic diseases, immunology, and oncology. Its lead program, SN-1011, is a potent and selective URAT1 inhibitor currently in Phase 2 clinical trials for the treatment of gout and hyperuricemia. Sinutra is also advancing SN-2101, a TYK2 inhibitor, for autoimmune conditions such as psoriasis. The company aims to deliver best-in-class medicines to address significant unmet medical needs globally.